Tag: Nuzyra

In 2018, the FDA approved omadacycline tosylate, a novel aminomethylcycline antibiotic, to combat severe and drug-resistant bacterial infections. This advanced medication was designed to overcome traditional tetracycline resistance mechanisms, offering a new therapeutic option for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Official patient instructions for the antibiotic Nuzyra (omadacycline) explicitly state to remain upright for at least 10 minutes after taking the medication. While this is a shorter period than required for some other tetracyclines, it remains a critical step to ensure safety and effectiveness.

Clinical studies have demonstrated that the oral bioavailability of omadacycline can be reduced by up to 63% when consumed with a meal containing dairy, compared to a fasted state. This significant reduction in absorption is the critical reason why you can't eat with Nuzyra, as it directly impacts the medication's ability to effectively treat serious infections.